---
schema_version: "secwatch.filing_event.v1"
accession: "0001714899-26-000086"
form_type: "8-K"
ticker: "DNLI"
cik: "0001714899"
company_name: "Denali Therapeutics Inc."
filed_at: "2026-07-28T01:01:17+00:00"
generated_at: "2026-07-28T10:05:12.907994+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Denali Therapeutics sells rare pediatric disease PRV for $195M

## Summary
- Gross proceeds of $195M from sale of PRV to a large pharmaceutical company.
- PRV received from FDA approval of AVLAYA (tividenofusp alfa) for Hunter syndrome in March 2026.
- Sale closed on July 27, 2026, per asset purchase agreement dated June 12, 2026.
- Proceeds provide significant cash infusion; no other terms disclosed.

## SEC filing metadata
- accession: 0001714899-26-000086
- form_type: 8-K
- ticker: DNLI
- cik: 0001714899
- company_name: Denali Therapeutics Inc.
- filed_at: 2026-07-28T01:01:17+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000086/0001714899-26-000086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000086/dnli-20260727.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001714899-26-000086
- JSON: https://secwatch.observer/filing/0001714899-26-000086.json
- Plain text: https://secwatch.observer/filing/0001714899-26-000086.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.